4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Valion Bio, Inc. (VBIO) operates in the Biotechnology industry and is headquartered in San Antonio, United States with about 52 employees. Its market capitalization is roughly $2 million. In the fiscal year ended 2025-12-31, VBIO reported $0M in revenue and ($9M) in net income.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $2M | — |
| Gross Profit | — | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($8M) | ($4M) | ($8M) | ($10M) | — |
| Net Income | ($9M) | ($6M) | ($8M) | ($10M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | ($0M) | $0M | $0M | $0M | — |
| Gross Profit | — | — | ($0M) | $0M | $0M | ($0M) |
| Operating Income (EBIT) | ($6M) | ($2M) | ($2M) | ($2M) | ($1M) | — |
| Net Income | ($6M) | ($3M) | ($3M) | ($2M) | ($2M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $32M | $3M | $5M | $6M | — |
| Total Liabilities | $15M | $0M | $2M | $2M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VBIO viewer.
About TickerBase · Data methodology & sources